Nasus Pharma (NSRX) Gains from Investment Securities (2024 - 2025)
Nasus Pharma (NSRX) reported Gains from Investment Securities of $810571.0 for Q4 2025, up 322.83% on a YoY basis from $191700.0 in Q4 2024, and up 322.83% quarter-over-quarter from $191700.0 in Q4 2024.
Nasus Pharma (NSRX) Gains from Investment Securities (2024 - 2025) Analysis & Trends
Nasus Pharma has reported Gains from Investment Securities for 2 years, with the latest figure at $810571.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities rose 322.83% year-over-year to $810571.0; the trailing twelve-month figure through Dec 2025 stood at $810571.0 (up 322.83% YoY), and the FY2025 full-year result was $810571.0, up 322.83% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at $810571.0, up from $191700.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $810571.0 in Q4 2025, with the low at $191700.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Nasus Pharma | 24.83 Mn | 20.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 810,571.00 |
| Dec 31, 2025 | 810,571.00 |
| Dec 31, 2024 | 191,700.00 |
| Dec 31, 2024 | 191,700.00 |